StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.68+1.03 (+3.25%)

Close on Nov 16, 2026Market cap $152.99MP/E –Yield –

Korsana Biosciences, Inc. saw revenue fall 12.6% to $1.90M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $152.99M.

Revenue
$1.90M
-12.6% vs. a year earlier
Operating income
-$6.82M
TTM Q2 2026
EPS, diluted
-$1.68
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$152.99M
P/E ratio
–
Price to sales
80.52
Price to book
30.07
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$1.90M
Net income
-$6.71M
EPS, diluted
-$1.68
Book value per share
$1.20
Diluted shares
4M

Trading

Previous close
$31.65
Open
$31.80
Day's range
$31.43 – $34.17
Volume
319,840
Average volume (20 days)
179,587
52-week range
$7.19 – $59.36
RSI (14 days)
55.3
Volatility (1 year)
326.9%
Relative volume
4.48×

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodKRSAS&P 500DifferenceKRSA per yearS&P 500 per year
1 month+0.9%-3.1%+4.0 pts
3 months+23.2%-4.5%+27.6 pts
Year to date+267.6%+9.4%+258.3 pts
1 year+243.3%+11.3%+232.0 pts
3 years+135.8%+70.4%+65.4 pts+33.1%+19.4%
5 years-91.1%+68.6%−159.7 pts-38.3%+11.0%

Nine years at a glance

Fiscal years 2017 to 2025 and trailing twelve months, USD

Revenue

$1.90M-12.6% YoY

Operating income

-$6.82M

Net income

-$6.71M

EPS, diluted

-$1.68

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Korsana Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Korsana Biosciences

Pharmaceutical Preparations

Cyclerion is a biopharmaceutical company that develops treatments for serious neuropsychiatric disorders. Its lead development candidate, CYC-126, is an individualized therapy for adult patients with treatment-resistant depression. The treatment combines two intravenous anesthetics, propofol and dexmedetomidine, with a patient monitoring and delivery tool that assists anesthesiologists during administration in hospital procedure rooms or post-anesthesia care units. The company also holds legacy soluble guanylate cyclase stimulator assets, including out-licensed programs for rare kidney conditions.

Company profile, executives and history

Korsana Biosciences stock: common questions

What is Korsana Biosciences's stock price?

KRSA closed at $32.68 on Nov 16, 2026, up 3.25% on the day. Over the past 52 weeks it traded between $7.19 and $59.36.

What is Korsana Biosciences's market cap?

Korsana Biosciences was worth $152.99M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is KRSA's P/E ratio?

Korsana Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.68), so it has no meaningful P/E ratio.

How much revenue does Korsana Biosciences make?

Korsana Biosciences reported revenue of $1.90M for the twelve months to Jun 30, 2026, down 12.6% from a year earlier.

Does Korsana Biosciences pay a dividend?

No. Korsana Biosciences has not paid a cash dividend over the last twelve months.

How has KRSA stock performed over the past year?

Including dividends, KRSA returned +243.3% over the past year, against +11.3% for the S&P 500.

Who are Korsana Biosciences's competitors?

Companies most similar to Korsana Biosciences by business, industry and size include OVID, NRXP, DNTH, NEUP, XENE.

See a number that looks wrong?